Helv Chir Acta. 1978 Jul;45(3):237-45.
Today neuropharmacas are a helpful part in the conservative treatment of the neurogenic bladder disorders. They are, or course, no "wonder-drugs" and usually lead to an improvement only of the troubles, but rarely to complete cure. If monotherapy does not lead to the results wanted, one should combine drugs of the same of similar effects but with different pharmacologic targets. A real progress was reached through alpha-receptor-blockers, whose use has, especially in children with myelomeningocele, changed the therapeutic concept in favour of a largely conservative treatment. We already know a number of substances that in one way or other influence the muscles of the bladder and the bladder outlet. If only part of them will reach clinical usage, it can be assumed that the pharmacotherapy will become even more meaningful in the treatment of neurogenic bladder disorders.
如今，神经药理学药物在神经源性膀胱疾病的保守治疗中发挥着有益作用。当然，它们并非“神药”，通常只能缓解症状，很少能实现完全治愈。如果单一疗法未能达到预期效果，应联合使用作用相同或相似但药理靶点不同的药物。α受体阻滞剂取得了实质性进展，其应用尤其在脊髓脊膜膨出患儿中，改变了治疗观念，更倾向于采用保守治疗。我们已经了解到许多以某种方式影响膀胱肌肉和膀胱出口的物质。如果其中只有一部分能应用于临床，可以推测药物治疗在神经源性膀胱疾病的治疗中将变得更有意义。
